Skip to main content
The American Journal of Managed Care has reviewed the approach to patients with interstitial lung disease (ILD); a significant cause of morbidity and mortality in those with systemic autoimmune rheumatic diseases (SARDs), including rheumatoid arthritis (RA), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM).
HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, Sout

Dr. John Cush RheumNow

10 months 1 week ago
HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, South American & Middle Eastern pop. B27 discerns clinical subsets of SpA and PsA, particularly acute anterior uveitis or axSpA with psoriasis, https://t.co/S4s0NvuwNY
High-Resolution CT in CTD-Interstitial Lung Disease

A systematic review and meta-analysis examined the role of high-re

Dr. John Cush RheumNow

10 months 1 week ago
High-Resolution CT in CTD-Interstitial Lung Disease A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs). https://t.co/9FmEe6BgN7
Our final webinar in this month's Rheum to Breathe: ILD campaign brings together ILD experts to discuss best practices i

Dr. John Cush RheumNow

10 months 1 week ago
Our final webinar in this month's Rheum to Breathe: ILD campaign brings together ILD experts to discuss best practices in diagnosis, screening, and monitoring, covering: tools, labs, and imaging; timing and frequency of screening; ILD screening in RA; and, referral strategies. https://t.co/Culzv9bSD4
Scleroderma-associated Interstitial Lung Disease

Since the first placebo-controlled randomized trial published nearly

Dr. John Cush RheumNow

10 months 1 week ago
Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/n8S0N2wTqu
Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years o

Dr. John Cush RheumNow

10 months 1 week ago
Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/IyCsJOm9PS https://t.co/PgDKanxaNU
Report of 54 Sjögren dz pts w/ cutaneous vasculitis (CV); most had cryoglobulinemic vasculitis & hypergammaglob.vas

Dr. John Cush RheumNow

10 months 1 week ago
Report of 54 Sjögren dz pts w/ cutaneous vasculitis (CV); most had cryoglobulinemic vasculitis & hypergammaglob.vasculitis. Sjogrens w/ CV had higher risk of lymphoma. Type II cryoglob. vasculitis incr risk of mortality/lymphoma, renal dz, peripheral nerve involvement https://t.co/Yd1iu9ZJX0
QD Clinic: ILD with Positive SSA and Rash

Dr. Elena Joerns, Rochester, Minnesota discusses a case of ILD with positive

Dr. John Cush RheumNow

10 months 1 week ago
QD Clinic: ILD with Positive SSA and Rash Dr. Elena Joerns, Rochester, Minnesota discusses a case of ILD with positive SSA and rash, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/Yuz8CuIN5H https://t.co/3M9emsIXVf
ILD and ANCA: What to do?

Several cohort studies conducted in Asia, Europe and the Americas have evaluated the clinica

Dr. John Cush RheumNow

10 months 1 week ago
ILD and ANCA: What to do? Several cohort studies conducted in Asia, Europe and the Americas have evaluated the clinical significance of ANCA when detected in patients with ILD as well as the types of ILD encountered in patients with microscopic polyangiitis (MPA) and their https://t.co/nrToywCaKm
Rheum to Breathe Journal Club

In this journal club, we will discuss two pivotal studies in ILD, the FIBRONEER study an

Dr. John Cush RheumNow

10 months 1 week ago
Rheum to Breathe Journal Club In this journal club, we will discuss two pivotal studies in ILD, the FIBRONEER study and the RECITAL study: Nerandomilast in Patients with Progressive Pulmonary Fibrosis, Maher, T.M. et al. NEJM. 2025 May 19. https://t.co/L0gIsP5nAn https://t.co/026GbJdCvJ
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA. 
Screening for RA-ILD: metanalysis of 9 studies, 1380 RA pts - RA-ILD prevalence ranged from 6.7-42.7%; 18.9% via HRCT.

Dr. John Cush RheumNow

10 months 1 week ago
Screening for RA-ILD: metanalysis of 9 studies, 1380 RA pts - RA-ILD prevalence ranged from 6.7-42.7%; 18.9% via HRCT. None examined risk factors. Male sex & smoking were ~12% higher in RA-ILD & RA disease onset age was 7 years higher in RA-ILD pts. DAS didnt https://t.co/qA2oitwQg5
CAR-T Product Shows Early Promise in Lupus

Five patients with systemic lupus erythematosus (SLE) in China have been tr

Dr. John Cush RheumNow

10 months 1 week ago
CAR-T Product Shows Early Promise in Lupus Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months. https://t.co/eg37PZK6kn
Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.
×